Supplementary Figure S5. ADU-S100 induces global changes in cytokine and chemokine production in the TME of non-tolerant, tumor-bearing FVB/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
posted on 2023-04-03, 23:23authored byJeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky, Leisha A. Emens
At 24 hours post IT injection of ADU-S100 or HBSS, cytokine and chemokine production within the TME of non-tumor bearing FVB/N mice were evaluated by ELISA. (A) Significant amounts of TNFα and IL-6 were produced in the TME in response to ADU-S100. (B) Significant amounts of CCL2, CCL5, and CCL11 were produced in the TME in response to ADU-S100. (C) Significant amounts of CXCL1 were produced in the TME in response to ADU-S100, whereas CXCL9 and CXCL10 were already highly expressed independent of ADU-S100 injection.